What difference will this make
Patient outcomes
The innovations developed through this Challenge will enable the patient voice to be expressed and captured in tangible ways, and used by clinicians to inform the ongoing management of their care:
- Patients can conveniently respond to questions and provide information in a safe and secure way.
- The NHS and clinicians can efficiently collate, analyse and use information reported by patients in a timely way.
Data science solutions
Seed funding through this Challenge provided the spring board for developing improved treatment for Malignant Pleural Mesothelioma (MPM):
Canon Medical Research Europe were awarded a £5m International Accelerator Award from Cancer Research UK for the PREDICT-Meso (PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma) Network.
This research programme – led by clinician scientist Professor Kevin Blyth (University of Glasgow /NHS Greater Glasgow & Clyde) – aims to close the gap on identifying key molecular events in the early stages of disease by focusing on understanding how asbestos-driven inflammation develops into MPM. Clinicians, pathologists, research scientists, bioinformaticians and clinical trial experts within PREDICT-Meso are working to translate these findings into effective diagnosis and early treatment for patients.
Impact Stories
The ways in which IHDP’s approach and activities contributed to improved outcomes and impact are shown through impact stories.